Illumina price target lowered to $135 from $145 at Canaccord

Canaccord analyst Kyle Mikson lowered the firm’s price target on Illumina (ILMN) to $135 from $145 and keeps a Hold rating on the shares. The firm said its target decrease is driven by uncertainty in China/NIH causing them to modify revenue and margin forecasts. Canaccord said while the company maintained its revenue guidance in the face of additional headwinds in China, they remain on the sidelines until tangible signs of sustainable solid performance are more apparent.